A Phase I, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of PRLX 93936 Administered Intravenously Daily for Five Days Followed by a 23-Day Rest Period in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 04 Jan 2012
At a glance
- Drugs PRLX 93936 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 04 Jan 2012 Actual patient number is 37 as reported by ClinicalTrials.gov.
- 04 Jan 2012 Actual end date Nov 2011 added as reported by ClinicalTrials.gov.
- 04 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.